These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34714686)

  • 1.
    Dahora LC; Verheul MK; Williams KL; Jin C; Stockdale L; Cavet G; Giladi E; Hill J; Kim D; Leung Y; Bobay BG; Spicer LD; Sawant S; Rijpkema S; Dennison SM; Alam SM; Pollard AJ; Tomaras GD
    Sci Immunol; 2021 Oct; 6(64):eabj1181. PubMed ID: 34714686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgA and IgG1 Specific to Vi Polysaccharide of
    Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
    Front Immunol; 2019; 10():2582. PubMed ID: 31781100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
    Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
    Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
    Front Immunol; 2020; 11():574057. PubMed ID: 33424833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen.
    Hart PJ; O'Shaughnessy CM; Siggins MK; Bobat S; Kingsley RA; Goulding DA; Crump JA; Reyburn H; Micoli F; Dougan G; Cunningham AF; MacLennan CA
    PLoS One; 2016; 11(1):e0145945. PubMed ID: 26741681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
    Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB
    Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
    Singh M; Ganguly NK; Kumar L; Vohra H
    Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
    Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
    Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles.
    Meena J; Kumar R; Singh M; Ahmed A; Panda AK
    Eur J Pharm Biopharm; 2020 Jul; 152():270-281. PubMed ID: 32470636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.
    Jossi SE; Arcuri M; Alshayea A; Persaud RR; Marcial-Juárez E; Palmieri E; Di Benedetto R; Pérez-Toledo M; Pillaye J; Channell WM; Schager AE; Lamerton RE; Cook CN; Goodall M; Haneda T; Bäumler AJ; Jackson-Jones LH; Toellner KM; MacLennan CA; Henderson IR; Micoli F; Cunningham AF
    Front Immunol; 2023; 14():1139329. PubMed ID: 37033932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vi-specific serological correlates of protection for typhoid fever.
    Jin C; Hill J; Gunn BM; Yu WH; Dahora LC; Jones E; Johnson M; Gibani MM; Spreng RL; Alam SM; Nebykova A; Juel HB; Dennison SM; Seaton KE; Fallon JK; Tomaras GD; Alter G; Pollard AJ
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33180929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies.
    Gibani MM; Voysey M; Jin C; Jones C; Thomaides-Brears H; Jones E; Baker P; Morgan M; Simmons A; Gordon MA; Cerundolo V; Pitzer VE; Angus B; Levine MM; Darton TC; Pollard AJ
    Clin Infect Dis; 2019 Apr; 68(8):1265-1273. PubMed ID: 30252031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
    Khanam F; Babu G; Rahman N; Liu X; Rajib NH; Ahmed SU; Hossen MI; Biswas PK; Kelly S; Thesis-Nyland K; Mujadidi Y; McMillan NAJ; Pollard AJ; Clemens JD; Qadri F
    Vaccine; 2023 May; 41(19):3137-3140. PubMed ID: 37061369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
    Kantele A; Pakkanen SH; Karttunen R; Kantele JM
    PLoS One; 2013; 8(4):e60583. PubMed ID: 23593253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
    Robbins JD; Robbins JB
    J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.